BEAM方案预处理自体干细胞移植治疗复发难治非霍奇金淋巴瘤  

Treatment of relapsed/refractory non-Hodgkin lymphoma by autologous hemotopoietic stem-cell transplantation with BEAM as conditioning regimen

作　　者：张涛[1] 白庆咸[1] 梁蓉[1] 杨岚[1] 顾宏涛[1] 高广勋[1] 董宝侠[1] 舒汨汨[1] 陈协群[1] 

机构地区：[1]第四军医大学西京医院血液内科,陕西西安710032

出　　处：《现代肿瘤医学》2012年第12期2618-2620,共3页Journal of Modern Oncology

摘　　要：目的:评价BEAM方案预处理条件下的自体造血干细胞移植(ASCT)对复发和难治性非霍奇金淋巴瘤(NHL)的疗效。方法:确诊的侵袭性NHL患者42例,其中难治者23例,复发者19例,经ESHAP化疗方案动员后行BEAM方案预处理ASCT。结果:患者均获得造血功能重建,移植后外周血中性粒细胞计数(ANC)≥0.5×109/L的中位时间为9d(平均7-20d);血小板≥20×109/L中位时间12d(平均6-25d)。随访时间12-78.5个月,中位随访时间35.5个月。中位生存时间32.6个月(2.0-78.5个月),3年总生存率(OS)为55.8%,3年无病生存率(DFS)为44.5%。结论:以BEAM方案化疗进行预处理的ASCT治疗,疗效肯定,患者耐受良好,可以作为复发或难治性侵袭型NHL挽救治疗的理想选择。Objective：To evaluate the efficacy and safety of autologous hemotopoietic stem cell transplantation（ASCT） for patients with relapsed/refractory non-Hodgkin lymphoma（NHL）.Methods：Forty-two patients with relapsed/refractory aggressive NHL were treated by ASCT in which ESHAP therapy was used as stem cell mobilization regimen,and BEAM therapy as conditioning regimen in year 2005 to 2010.These patients were followed-up and data were collected and analysed to determine the efficacy,toxicity and long-term outcome.Results：All patients engrafted completely.The time of ANC≥0.5×109 and platelet count≥20×109/L were at 9d（7-20d） and 12d（6-25d） respectively.The median follow-up time was 35.5 months（12-78.5 months）;The median survival time was 32.6 months（2.0-78.5 months）;The estimated 3-year overall survival（OS） was 55.8%;The estimated 3-year disease-free survival（DFS） was 44.5%.Conclusion：ASCT using BEAM as conditioning regimen is a safe and effective therapy,and can be used as a choice of salvage for relapsed/refractory non-Hodgkin lymphoma patients.

关 键 词：非霍奇金淋巴瘤 复发或难治 造血干细胞移植 自体 BEAM预处理方案 

分 类 号：R733.1[医药卫生—肿瘤]